🧬 Where do we go next in kidney cancer? At #GlobalForum25 in Portugal, Dr. Axel Bex shared how future RCC studies may shift toward platform trials that pit new strategies against Pembrolizumab (our current standard). The vision: 1️⃣ Pretreat patients 2️⃣ Perform nephrectomy 3️⃣ Use pathologic response T-cell infiltrates 4️⃣ Decide who truly needs adjuvant therapy Because if a patient shows no pathologic response and no immune activity… why commit them to 9 more months of Pembrolizumab? | OncoAl

Dr. Shields on Optimal Adjuvant Therapy for CRC | OncLive